Interleukin-1β and Cancer.

Rébé C, Ghiringhelli F. · 2020

Read Interleukin-1β and Cancer. by Rébé C, Ghiringhelli F. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7408158.txt.

Introduction

Rébé and Ghiringhelli review interleukin-1 beta in cancer in Cancers. Inside a tumor, this inflammatory signal is made by immune cells, fibroblasts, and cancer cells themselves. Making it takes two steps: priming switches the gene on, then an inflammasome activates the cutting enzyme that matures it.

Once released, IL-1 beta drives gene programs in target cells and acts on immunity, blood vessel growth, cancer cell growth, migration, and spread. Cancer treatments themselves can provoke its release, with opposite effects on progression. That ambiguity frames the review's core question: should doctors block IL-1 beta in cancer treatment, and when? Gene variants and cell context steer the answer, the authors show.

Catalog record

CREATORRébé C, Ghiringhelli F.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE119 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7408158

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Interleukin-1β and Cancer By Cédric Rébé, François Ghiringhelli Published in: Cancers DOI: 10.3390/cancers12071791 ABSTRACT Within a tumor, IL-1β is produced and secreted by various cell types, such as immune cells, fibroblasts, or cancer cells. The IL1B gene is induced after “priming” of the cells and a second signal is required to allow IL-1β maturation by inflammasome-activated caspase-1. IL-1β is then released and leads to transcription of target genes through its ligation with IL-1R1 on target cells. IL-1β expression and maturation are guided by gene polymorphisms and by the cellular context. In cancer, IL-1β has pleiotropic effects on immune cells, angiogenesis, cancer cell proliferation, migration, and metastasis. Moreover, anti-cancer treatments are able to promote IL-1β production by cancer or immune cells, with opposite effects on cancer progression. This raises the question of whether or not to use IL-1β inhibitors in cancer treatment. 1. INTRODUCTION The IL-1 family includes four main members, namely, IL-1α, IL-1β, IL-33, and IL-1 receptor antagonist (IL-1RA). IL-1α, IL-1β, and IL-33 are cytokine activators, while IL-1RA is an inhibitory cytokine [1]. IL-1 cytokines bind the type 1 receptor (IL-1R1), except IL-33, which binds IL-1R4 (ST2). While IL-1α or IL-1β fixation on IL-1R1 induces a downstream signaling cascade and the transcription of several genes involved in inflammatory and immune pathways, IL-RA fixation does not have the same effect [2]. IL-1α and IL-1β are encoded by two different genes, with a low degree of sequence homology. They are both synthesized as preform proteins, pro-IL-1α and pro-IL-1β. Pro-IL-1β needs to be converted into IL-1β (by inflammatory caspase cleavage) to be active, whereas pro-IL-1α is active, and its cleavage into IL-1α (by calpain) will modulate its activity [3]. IL-1α can be localized in the nucleus, where it acts as a transcription factor to regulate cell differentiation in normal cells, as well as neoplasia in cancer cells. However, when cells undergo cell death, such as necrosis, IL-1α translocates into the cytosol and is released into the extracellular space to act as an « alarmin » [3,4]. In contrast, the synthesis and processing of IL-1β are tightly controlled and require two signals, namely “priming” to allow transcription of the IL1B gene and the activation signal, which leads to activation of inflammasome complexes and inflammatory caspases to cleave pro-IL-1β into mature IL-1β [5]. Although IL-1β and IL-1α share similar transducing pathways, they have different expression and activation processes, explaining why they have different biological and physiological effects in many diseases, notably cancer. 1.1. IL-1β Production Within the tumor, IL-1β is produced and secreted by various cell types, such as immune cells, fibroblasts, or cancer cells. However, the mechanisms of IL-1β production have been most widely studied in immune cells, particularly in myeloid cells, such as macrophages. As mentioned above, IL-1β production requires two signals, namely “priming” and cleavage (Figure 1). 1.1.1. “Priming” “Priming” corresponds to the transcription of the Il1b/IL1B gene, and is induced mainly by activation of the toll-like-receptors (TLRs), namely lipopolysaccharides (LPS), but also by tumor necrosis factor (TNF) α, through the TNF receptor or IL-1β itself (Figure 1). TLRs and IL-1R1 recruit the same adaptor protein, myeloid differentiation primary response 88 (Myd88), through their intra-cellular domain, which in turn activates interleukin-1 receptor-associated kinase 1/4 (IRAK1/4) and the TNFR-associated factor 6 (TRAF6) pathway. TNFR recruits TNFR1-associated death domain (TRADD), which activates the TRAF2/5 and receptor interacting protein 1 (RIP1) pathway. All these signaling cascades are able to activate nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) [6,7]. As hypoxia is an important event within the tumor, hypoxia-induced factor 1 (HIF1) was shown to regulate Il1b/IL1B transcription. Other classical transcription factors were also shown to induce Il1b/IL1B expression in myeloid cells, such as CCAAT/enhancer binding protein (C/EBP-)β, Interferon response factors 4 or 8 (IRF4/8) and PU.1 or protein kinase C (PKC)/activator protein-1 (AP-1), directly or through Myd88 [6]. The STAT1 pathway was also shown to be required in macrophages to enable IL-1β production [8]. Finally, single nucleotide polymorphisms (SNPs) in the Il1b/IL1B gene or promoter can affect Il1b/IL1B transcription by inhibiting the fixation of the transcription factors described above or by allowing the fixation of repressor factors. After transcription/translation, pro-IL-1β is produced as an inactive, 31kDa protein that needs to be cleaved into 17kDa IL-1β to become active. 1.1.2. Inflammasomes To be activated, pro-IL-1β needs to be cleaved by proteases. Although cleavage by cathepsin G or elastase in neutrophils has been described, yielding low-activity IL-1β, caspases are the main proteases that can provide fully-active IL-1β. Caspase-8 has been shown to cleave IL-1β in vitro and in specific conditions. However, the most important enzyme involved in IL-1β maturation remains caspase-1, which has been reported to be activated via numerous sources [9]. Caspase-1 activation occurs via recruitment to multi-protein complexes called inflammasomes. These intracellular complexes are all composed of a receptor and an adaptor, allowing recruitment and activation of pro-inflammatory caspases [5]. The receptors, called nucleotide-binding oligomerization domain-containing protein (Nod)-like receptors (or NLR), recognize a wide variety of stimuli referred to as pathogen-associated molecular patterns (PAMPs) (Figure 1). The NLR family is characterized by the presence of several specific domains. All of these proteins have a central NACHT ((NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC (major histocompatibility complex) class 2 transcription activator), HET-E (incompatibility locus protein from Podospora anserina), and TP1 (telomerase-associated protein)) domain, responsible for complex activation, via ATP-dependent oligomerization. At the C-terminal, the leucine-rich domain (LRR) is involved in ligand detection and in complex self-regulation. The N-terminal is either a pyrin domain (PYD) or a caspase recruitment domain (CARD) involved in protein–protein interactions for signal transduction. Thus, activated receptors can recruit either pro-caspases (via the CARD) or an adaptor protein (via the PYD), which in turn will recruit a pro-caspase. The NLR receptors are divided into four families, with many members, according to the N-terminal domain composition. However, the NOD-LRR and pyrin containing protein 3 (NLRP3) is the most important receptor, and is responsible for caspase-1 activation under sterile conditions [5,10]. Prior to its activation, the expression of NLRP3 is under the control of NF-κB activation, like IL-1β. NLRP3 is activated by a wide variety of stimuli and by three non-exclusive pathways, with possible crosstalk. The first is intracellular K+ efflux induced by binding of extra-cellular ATP to its receptor P2X7. The second involves phagocytosis of crystalline structures and subsequent lysosome damage. Lysosomal content, especially cathepsin B, will then activate NLRP3 through direct interaction. The third pathway involves an increase in reactive oxygen species (ROS) synthesis. All these steps will converge to NLRP3 activation, recruitment of ASC (apoptosis associated speck-like protein containing a CARD domain) and pro-caspase-1, and IL-1β and IL-18 maturation [11,12]. 1.1.3. Secretion The mechanisms that lead to IL-1β secretion are not clear (Figure 1). This might be explained by the existence of several pathways that may or may not co-exist, depending on the context (Figure 1). Studies of IL-1β secretion used different experimental settings, such as in vivo, ex vivo, or in vitro cultures; different cellular models (primary cells, cell lines) and cell types (macrophages, fibroblasts, neutrophils); several activators that induce cell death or not (pyroptosis, necrosis); as well as different techniques to detect IL-1β (ELISA, Western blot, IL-1 HEK-blue cells). Moreover, techniques used to investigate IL-1β secretion pathways, such as electronic

Read the complete text